These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31855703)

  • 21. Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival.
    Al-Ahmadi A; Ardeshir-Larijani F; Fu P; Cao S; Lipka MB; Dowlati A; Bruno DS
    Clin Lung Cancer; 2021 Jan; 22(1):16-22.e1. PubMed ID: 33397584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in genes connected with the TCF7L2 transcription factor are associated with a poor prognosis in non-small cell lung cancer.
    Rice SJ; Liu X; Hyland V; Liu Z; Belani CP
    Lung Cancer; 2020 Mar; 141():97-100. PubMed ID: 31986371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis.
    Hou H; Zhang C; Qi X; Zhou L; Liu D; Lv H; Li T; Sun D; Zhang X
    Cancer Biol Ther; 2020; 21(1):26-33. PubMed ID: 31594446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
    Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
    Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
    Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
    J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach.
    Chang JC; Alex D; Bott M; Tan KS; Seshan V; Golden A; Sauter JL; Buonocore DJ; Vanderbilt CM; Gupta S; Desmeules P; Bodd FM; Riely GJ; Rusch VW; Jones DR; Arcila ME; Travis WD; Ladanyi M; Rekhtman N
    Clin Cancer Res; 2019 Dec; 25(23):7113-7125. PubMed ID: 31471310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
    Adib E; Nassar AH; Abou Alaiwi S; Groha S; Akl EW; Sholl LM; Michael KS; Awad MM; Jӓnne PA; Gusev A; Kwiatkowski DJ
    Genome Med; 2022 Apr; 14(1):39. PubMed ID: 35428358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
    Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
    Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing.
    Chun YJ; Choi JW; Hong MH; Jung D; Son H; Cho EK; Min YJ; Kim SW; Park K; Lee SS; Kim S; Kim HR; Cho BC;
    PLoS One; 2019; 14(11):e0224379. PubMed ID: 31765373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience.
    Dall'Olio FG; Conci N; Rossi G; Fiorentino M; De Giglio A; Grilli G; Altimari A; Gruppioni E; Filippini DM; Di Federico A; Nuvola G; Ardizzoni A
    Lung Cancer; 2020 Nov; 149():5-9. PubMed ID: 32932213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
    Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
    PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC).
    Liao J; Shen J; Leng Q; Qin M; Zhan M; Jiang F
    Thorac Cancer; 2020 Mar; 11(3):762-768. PubMed ID: 31994346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
    Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden.
    van den Heuvel GRM; Kroeze LI; Ligtenberg MJL; Grünberg K; Jansen EAM; von Rhein D; de Voer RM; van den Heuvel MM
    Respir Res; 2021 Nov; 22(1):302. PubMed ID: 34819052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
    Gibert J; Clavé S; Hardy-Werbin M; Taus Á; Rocha P; Longarón R; Piquer G; Chaib I; Carcereny E; Morán T; Salido M; Dalmases A; Bellosillo B; Arriola E
    Lung Cancer; 2020 Feb; 140():42-45. PubMed ID: 31862576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.